Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dyba, T.; Randi, G.; Bray, F.; Martos, C.; Giusti, F.; Nicholson, N.; Gavin, A.; Flego, M.; Neamtiu, L.; Dimitrova, N.; et al. The European Cancer Burden in 2020: Incidence and Mortality Estimates for 40 Countries and 25 Major Cancers. Eur. J. Cancer 2021, 157, 308–347. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics. CA Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [PubMed]
- Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; et al. Design and End Points of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26, 1148. [Google Scholar] [CrossRef]
- Aggarwal, R.; Ryan, C.J. Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment. Oncologist 2011, 16, 264–275. [Google Scholar] [CrossRef]
- Cornford, P.; Bellmunt, J.; Bolla, M.; Briers, E.; De Santis, M.; Gross, T.; Henry, A.M.; Joniau, S.; Lam, T.B.; Mason, M.D.; et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur. Urol. 2017, 71, 630–642. [Google Scholar] [CrossRef] [PubMed]
- Foster, C.C.; Weichselbaum, R.R.; Pitroda, S.P. Oligometastatic Prostate Cancer: Reality or Figment of Imagination? Cancer 2019, 125, 340–352. [Google Scholar] [CrossRef]
- Weichselbaum, R.R.; Hellman, S. Oligometastases Revisited. Nat. Rev. Clin. Oncol. 2011, 8, 378–382. [Google Scholar] [CrossRef]
- Hellman, S.; Weichselbaum, R.R. Oligometastases. J. Clin. Oncol. 1995, 13, 8–10. [Google Scholar] [CrossRef]
- Kyriakopoulos, C.E.; Chen, Y.-H.; Carducci, M.A.; Liu, G.; Jarrard, D.F.; Hahn, N.M.; Shevrin, D.H.; Dreicer, R.; Hussain, M.; Eisenberger, M.; et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J. Clin. Oncol. 2018, 36, 1080–1087. [Google Scholar] [CrossRef]
- Niibe, Y.; Hayakawa, K. Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn. J. Clin. Oncol. 2010, 40, 107–111. [Google Scholar] [CrossRef] [PubMed]
- Mottet, N.; van den Bergh, R.C.N.; Briers, E.; Van den Broeck, T.; Cumberbatch, M.G.; De Santis, M.; Fanti, S.; Fossati, N.; Gandaglia, G.; Gillessen, S.; et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2021, 79, 243–262. [Google Scholar] [CrossRef] [PubMed]
- Gillessen, S.; Attard, G.; Beer, T.M.; Beltran, H.; Bossi, A.; Bristow, R.; Carver, B.; Castellano, D.; Chung, B.H.; Clarke, N.; et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur. Urol. 2018, 73, 178–211. [Google Scholar] [CrossRef] [PubMed]
- Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I.; et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N. Engl. J. Med. 2004, 351, 1502–1512. [Google Scholar] [CrossRef] [PubMed]
- de Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.-P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; et al. Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial. Lancet 2010, 376, 1147–1154. [Google Scholar] [CrossRef] [PubMed]
- Ryan, C.J.; Smith, M.R.; Fizazi, K.; Saad, F.; Mulders, P.F.A.; Sternberg, C.N.; Miller, K.; Logothetis, C.J.; Shore, N.D.; Small, E.J.; et al. Abiraterone Acetate plus Prednisone versus Placebo plus Prednisone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. Lancet Oncol. 2015, 16, 152–160. [Google Scholar] [CrossRef] [PubMed]
- Saad, F. Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer. Ther. Adv. Urol. 2013, 5, 201–210. [Google Scholar] [CrossRef] [PubMed]
- Decaestecker, K.; De Meerleer, G.; Lambert, B.; Delrue, L.; Fonteyne, V.; Claeys, T.; De Vos, F.; Huysse, W.; Hautekiet, A.; Maes, G.; et al. Repeated Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence. Radiat. Oncol. 2014, 9, 135. [Google Scholar] [CrossRef] [PubMed]
- Tree, A.C.; Khoo, V.S.; Eeles, R.A.; Ahmed, M.; Dearnaley, D.P.; Hawkins, M.A.; Huddart, R.A.; Nutting, C.M.; Ostler, P.J.; van As, N.J. Stereotactic Body Radiotherapy for Oligometastases. Lancet Oncol. 2013, 14, e28–e37. [Google Scholar] [CrossRef]
- Ahmed, H.U.; Freeman, A.; Kirkham, A.; Sahu, M.; Scott, R.; Allen, C.; Van der Meulen, J.; Emberton, M. Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial. J. Urol. 2011, 185, 1246–1254. [Google Scholar] [CrossRef]
- Palma, D.A.; Olson, R.; Harrow, S.; Gaede, S.; Louie, A.V.; Haasbeek, C.; Mulroy, L.; Lock, M.; Rodrigues, G.B.; Yaremko, B.P.; et al. Stereotactic Ablative Radiotherapy versus Standard of Care Palliative Treatment in Patients with Oligometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-Label Trial. Lancet 2019, 393, 2051–2058. [Google Scholar] [CrossRef] [PubMed]
- De Bleser, E.; Jereczek-Fossa, B.A.; Pasquier, D.; Zilli, T.; Van As, N.; Siva, S.; Fodor, A.; Dirix, P.; Gomez-Iturriaga, A.; Trippa, F.; et al. Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur. Urol. 2019, 76, 732–739. [Google Scholar] [CrossRef] [PubMed]
- Ost, P.; Reynders, D.; Decaestecker, K.; Fonteyne, V.; Lumen, N.; De Bruycker, A.; Lambert, B.; Delrue, L.; Bultijnck, R.; Claeys, T.; et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J. Clin. Oncol. 2018, 36, 446–453. [Google Scholar] [CrossRef] [PubMed]
- Hölscher, T.; Baumann, M.; Kotzerke, J.; Zöphel, K.; Paulsen, F.; Müller, A.-C.; Zips, D.; Koi, L.; Thomas, C.; Löck, S.; et al. Toxicity and Efficacy of Local Ablative, Image-Guided Radiotherapy in Gallium-68 Prostate-Specific Membrane Antigen Targeted Positron Emission Tomography-Staged, Castration-Sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. Eur. Urol. Oncol. 2022, 5, 44–51. [Google Scholar] [CrossRef] [PubMed]
- Phillips, R.; Shi, W.Y.; Deek, M.; Radwan, N.; Lim, S.J.; Antonarakis, E.S.; Rowe, S.P.; Ross, A.E.; Gorin, M.A.; Deville, C.; et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020, 6, 650–659. [Google Scholar] [CrossRef] [PubMed]
- Ingrosso, G.; Detti, B.; Fodor, A.; Caini, S.; Borghesi, S.; Triggiani, L.; Trippa, F.; Russo, D.; Bruni, A.; Francolini, G.; et al. Stereotactic Ablative Radiotherapy in Castration-Resistant Prostate Cancer Patients with Oligoprogression during Androgen Receptor-Targeted Therapy. Clin. Transl. Oncol. 2021, 23, 1577–1584. [Google Scholar] [CrossRef] [PubMed]
- Deek, M.P.; Van der Eecken, K.; Sutera, P.; Deek, R.A.; Fonteyne, V.; Mendes, A.A.; Decaestecker, K.; Kiess, A.P.; Lumen, N.; Phillips, R.; et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J. Clin. Oncol. 2022, 40, 3377–3382. [Google Scholar] [CrossRef]
- Franzese, C.; Perrino, M.; Marzo, M.A.; Badalamenti, M.; Baldaccini, D.; D’Agostino, G.; Marini, B.; De Vincenzo, F.; Zucali, P.A.; Scorsetti, M. Oligoprogressive Castration-Resistant Prostate Cancer Treated with Metastases-Directed Stereotactic Body Radiation Therapy: Predictive Factors for Patients’ Selection. Clin. Exp. Metastasis 2022, 39, 449–457. [Google Scholar] [CrossRef] [PubMed]
- Miszczyk, M.; Rajwa, P.; Yanagisawa, T.; Nowicka, Z.; Shim, S.R.; Laukhtina, E.; Kawada, T.; von Deimling, M.; Pradere, B.; Rivas, J.G.; et al. The Efficacy and Safety of Metastasis-Directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Eur. Urol. 2023, 85, 125–138. [Google Scholar] [CrossRef]
- Marvaso, G.; Volpe, S.; Pepa, M.; Augugliaro, M.; Corrao, G.; Biffi, A.; Zaffaroni, M.; Bergamaschi, L.; La Fauci, F.M.; Mistretta, F.A.; et al. Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-Analysis of Prospective Studies. Eur. Urol. Open Sci. 2021, 27, 19–28. [Google Scholar] [CrossRef]
- Massaro, M.; Facondo, G.; Vullo, G.; Aschelter, A.M.; Rossi, A.; De Sanctis, V.; Marchetti, P.; Osti, M.F.; Valeriani, M. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. Front. Oncol. 2021, 11, 695136. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.-C.; Bajwa, R.; Bari, S.; Ali, A.; Skelton, W.P.; Federico, R.-A.; Bishnoi, R.; Wray, J.W.; Zlotecki, R.A.; Dang, L.H.; et al. Stereotactic Body Radiation Therapy for the Treatment of Oligoprogression on Androgen Receptor Targeted Therapy in Castration-Resistant Prostate Cancer. Oxf. Med. Case Rep. 2018, 2018, omx078. [Google Scholar] [CrossRef] [PubMed]
- Lohaus, F.; Zöphel, K.; Löck, S.; Wirth, M.; Kotzerke, J.; Krause, M.; Baumann, M.; Troost, E.G.C.; Hölscher, T. Can Local Ablative Radiotherapy Revert Castration-Resistant Prostate Cancer to an Earlier Stage of Disease? Eur. Urol. 2019, 75, 548–551. [Google Scholar] [CrossRef] [PubMed]
- Berghen, C.; Joniau, S.; Ost, P.; Poels, K.; Everaerts, W.; Decaestecker, K.; Haustermans, K.; Devos, G.; De Meerleer, G. Progression-Directed Therapy for Oligoprogression in Castration-Refractory Prostate Cancer. Eur. Urol. Oncol. 2021, 4, 305–309. [Google Scholar] [CrossRef] [PubMed]
- Deek, M.P.; Taparra, K.; Phillips, R.; Velho, P.I.; Gao, R.W.; Deville, C.; Song, D.Y.; Greco, S.; Carducci, M.; Eisenberger, M.; et al. Metastasis-Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer. Eur. Urol. Oncol. 2021, 4, 447–455. [Google Scholar] [CrossRef] [PubMed]
- Onal, C.; Kose, F.; Ozyigit, G.; Aksoy, S.; Oymak, E.; Muallaoglu, S.; Guler, O.C.; Tilki, B.; Hurmuz, P.; Akyol, F. Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients during Abiraterone/Enzalutamide Treatment. Prostate 2021, 81, 543–552. [Google Scholar] [CrossRef]
- Yoshida, S.; Takahara, T.; Arita, Y.; Ishii, C.; Uchida, Y.; Nakagawa, K.; Toda, K.; Sakamoto, T.; Kijima, T.; Yokoyama, M.; et al. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, 376–381. [Google Scholar] [CrossRef] [PubMed]
- Triggiani, L.; Mazzola, R.; Magrini, S.M.; Ingrosso, G.; Borghetti, P.; Trippa, F.; Lancia, A.; Detti, B.; Francolini, G.; Matrone, F.; et al. Metastasis-Directed Stereotactic Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer: A Multicenter Study. World J. Urol. 2019, 37, 2631–2637. [Google Scholar] [CrossRef]
- Baron, D.; Pasquier, D.; Pace-Loscos, T.; Vandendorpe, B.; Schiappa, R.; Ortholan, C.; Hannoun-Levi, J.M. Stereotactic Body Radiation Therapy to Postpone Systemic Therapy Escalation for Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Clin. Transl. Radiat. Oncol. 2023, 45, 100710. [Google Scholar] [CrossRef]
- | Age | PSA Baseline | Systemic Therapy Line | Ongoing Systemic Therapy | Nodal GTV [N] | Bone GTV [N] |
---|---|---|---|---|---|---|
pt1 | 71 | 8.2 | II | ADT + Abi | 0 | 1 |
pt2 | 74 | 14.3 | III | ADT + Enza | 2 | 3 |
pt3 | 68 | 0.6 | III | ADT + Doce | 1 | 1 |
pt4 | 65 | 0.5 | II | ADT + Abi | 0 | 1 |
pt5 | 48 | 0.5 | III | ADT + Enza | 0 | 1 |
pt6 | 74 | 0.8 | I | ADT | 1 | 1 |
pt7 | 64 | 0.6 | I | ADT | 1 | 0 |
pt8 | 82 | 1.3 | II | ADT + Abi | 0 | 2 |
pt9 | 73 | 14 | III | ADT + Abi | 0 | 2 |
pt10 | 76 | 1.1 | I | ADT | 1 | 0 |
pt11 | 58 | 0.2 | I | ADT + Apa | 1 | 0 |
PATIENT | PSA Resp | B-Rel | R-Prog | P-Met Prog | LC | NEST |
---|---|---|---|---|---|---|
pt1 | Yes | Yes | Yes | Yes | Yes | Yes |
pt2 | Yes | Yes | Yes | Yes | Yes | Yes |
pt3 | No | Yes | Yes | No | Yes | Yes |
pt4 | Yes | Yes | Yes | Yes | Yes | Yes |
pt5 | No | Yes | Yes | Yes | Yes | Yes |
pt6 | Yes | No | No | No | Yes | No |
pt7 | Yes | No | No | No | Yes | No |
pt8 | Yes | No | No | No | Yes | No |
pt9 | Yes | Yes | Yes | Yes | Yes | Yes |
pt10 | Yes | No | No | No | Yes | No |
pt11 | Yes | No | Yes | Yes | Yes | No |
N. | 9 | 6 | 7 | 6 | 11 | 6 |
- | FUP | b-PFS | r-PFS | FPP | LC | NEST-FS |
---|---|---|---|---|---|---|
pt1 | 63 | 23 | 25 | 61 | 63 | 35 |
pt2 | 25 | 9 | 6 | 24 | 25 | 10 |
pt3 | 9 | 4 | 4 | 9 | 9 | 6 |
pt4 | 32 | 18 | 19 | 19 | 32 | 19 |
pt5 | 14 | 6 | 10 | 10 | 14 | 7 |
pt6 | 19 | 19 | 19 | 19 | 19 | 32 |
pt7 | 50 | 50 | 50 | 50 | 50 | 14 |
pt8 | 12 | 12 | 12 | 12 | 12 | 19 |
pt9 | 13 | 13 | 12 | 12 | 13 | 13 |
pt10 | 61 | 61 | 61 | 61 | 61 | 12 |
pt11 | 7 | 7 | 3 | 3 | 7 | 7 |
Median time | 19 | 13 | 12 | 19 | 19 | 13 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chioccola, E.; Caroprese, M.; Goodyear, C.A.; Barillaro, A.; Oliviero, C.; Clemente, S.; Feoli, C.; Formisano, L.; Farella, A.; Cella, L.; et al. Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases. Radiation 2024, 4, 115-124. https://doi.org/10.3390/radiation4020009
Chioccola E, Caroprese M, Goodyear CA, Barillaro A, Oliviero C, Clemente S, Feoli C, Formisano L, Farella A, Cella L, et al. Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases. Radiation. 2024; 4(2):115-124. https://doi.org/10.3390/radiation4020009
Chicago/Turabian StyleChioccola, Emanuele, Mara Caroprese, Christina A. Goodyear, Angela Barillaro, Caterina Oliviero, Stefania Clemente, Chiara Feoli, Luigi Formisano, Antonio Farella, Laura Cella, and et al. 2024. "Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases" Radiation 4, no. 2: 115-124. https://doi.org/10.3390/radiation4020009